Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in plantibody technology.

E Stoger1, M Sack, L Nicholson

  • 1Institute for Molecular Biotechnology, Biology VII, RWTH Aachen, Worringerweg 1, 52074 Aachen, Germany. stoger@molbiotech.rwth-aachen.de

Current Pharmaceutical Design
|July 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic insights into multiple system atrophy from a PLP-α-synuclein transgenic mouse model.

Brain research·2024
Same author

Efficacy and Safety outcomes of a novel model to assess new medical retina referrals in a high-volume medical retina virtual clinic.

Eye (London, England)·2023
Same author

Predictors of complex PTSD: the role of trauma characteristics, dissociation, and comorbid psychopathology.

Borderline personality disorder and emotion dysregulation·2023
Same author

Targeted genome editing of plants and plant cells for biomanufacturing.

Transgenic research·2021
Same author

[Targeted treatment of posttraumatic disorders-what can confrontation therapy achieve?]

Der Unfallchirurg·2021
Same author

Pulse treatments of penicillin-G and streptomycin minimise internal infections and have post-treatment effects on the morphogenesis of ginseng root culture.

Plant cell reports·2019
Same journal

Corrigendum to: miRNA in Diagnosis and Therapeutics of Tuberculosis: Importance in Latent and Brain Associated Pathologies.

Current pharmaceutical design·2026
Same journal

Combining Network Pharmacology, Machine Learning, Molecular Docking, and Experimental Validation to Explore the Mechanism of Danggui-Shaoyao-San in treating Rheumatoid arthritis.

Current pharmaceutical design·2026
Same journal

Clinical Utilization of Beers Criteria and STOPP-START Algorithm in Elderly Patients: Emphasis on Neuropsychiatric Medications.

Current pharmaceutical design·2026
Same journal

Halofantrine Upregulates ATP6V0D2 and Induces Cytotoxic Autophagy in GBM Models.

Current pharmaceutical design·2026
Same journal

Multi-Component Synergy in Hepatic Trauma Repair: Network Pharmacology and Molecular Docking Decipher Panax Notoginseng's PI3K-Akt Pathway Activation.

Current pharmaceutical design·2026
Same journal

Network Pharmacology Analysis and Animal Experiment Validation of Penthorum chinense Pursh in Treating Cholestatic Liver Disease.

Current pharmaceutical design·2026
See all related articles

Plants offer a cost-effective, scalable alternative for producing therapeutic antibodies, known as plantibodies. While glycosylation differences are being studied, plant-based antibody production shows promise for pharmaceutical development.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Pharmaceutical Science

Background:

  • Antibodies are crucial for disease prevention, treatment, and diagnosis.
  • Current recombinant antibody production relies heavily on microbial and mammalian cell systems, facing capacity limitations.
  • There is a growing demand for cost-effective and scalable antibody production methods.

Purpose of the Study:

  • To evaluate plants as a viable system for cost-effective antibody production.
  • To discuss the advantages of plant-based antibody production (plantibodies) over traditional methods.
  • To address challenges and future prospects of plantibody development for pharmaceutical applications.

Main Methods:

  • Review of current literature on plant-based antibody production.

Related Experiment Videos

  • Analysis of plantibody performance in clinical trials.
  • Identification of biochemical and regulatory challenges in plantibody manufacturing.

    • Main Results:

    • Plants are emerging as efficient 'green bioreactors' for antibody production, offering cost, scalability, and safety benefits.
    • Several plantibodies are in clinical trials, indicating promising early-stage performance.
    • Differences in glycosylation between plantibodies and mammalian antibodies have been identified and are under scientific evaluation.

    Conclusions:

    • Plant-based antibody production presents a cost-effective and scalable alternative to traditional systems.
    • Ongoing research aims to optimize plantibody yield, homogeneity, and authenticity for therapeutic use.
    • Regulatory hurdles and implementation of Good Manufacturing Practice (GMP) are key challenges for widespread adoption in the pharmaceutical industry.